VEGF: A Key Factor in Angiogenesis and Clinical

Hits:18   Date: 12/8/2025

Applications
Vascular Endothelial Growth Factor (VEGF) is a major cytokine involved in regulating angiogenesis, vascular permeability, and tumor progression. VEGF and its receptors play significant roles in various physiological and pathological conditions, particularly in cancer, ophthalmic diseases, and cardiovascular diseases. With an increasing understanding of VEGF’s molecular mechanisms, it has become a crucial target in biomedical research, particularly in the context of targeted therapies.

 
This article explores the molecular structure and mechanisms of VEGF, its roles in angiogenesis, oncology, ophthalmology, and cardiovascular diseases, and discusses the clinical applications of VEGF inhibitors. It also provides a glimpse into future research directions regarding VEGF.
 
Molecular Structure and Mechanism of VEGF
VEGF is a biologically active protein that belongs to the family of angiogenic factors. The family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, among others, with VEGF-A being the most extensively studied and applied. The primary function of VEGF-A is to promote the proliferation, migration, and formation of new blood vessels, which is crucial for various physiological and pathological processes.
 
Structural Features of VEGF-A
VEGF-A’s molecular structure is unique, consisting of multiple domains rich in cysteine residues, which help VEGF bind to its receptors. VEGF-A forms dimers through two conserved cysteine residues at its C-terminus, mediating binding to the vascular endothelial growth factor receptors (VEGFR-1 and VEGFR-2). VEGFR-2 is considered the primary receptor for VEGF-A, especially in the context of angiogenesis.
 
Upon binding to VEGFR-2, VEGF activates downstream signaling pathways, including PI3K/Akt, MAPK, and PLC-γ, all of which promote endothelial cell proliferation, migration, and vascular permeability, facilitating the formation of new blood vessels. This process is not only critical for normal physiological processes like wound healing and the menstrual cycle, but also plays a significant role in many pathological states, such as tumors and retinal diseases.
 
VEGF Receptors and Their Signaling Pathways
VEGF receptors are the core targets of VEGF, with VEGFR-1, VEGFR-2, and VEGFR-3 being the primary receptors. VEGFR-1 and VEGFR-2 are mainly expressed on endothelial cells, while VEGFR-3 is primarily found on lymphatic endothelial cells. VEGFR-2 is the major receptor for VEGF-A and plays a key role in angiogenesis. The role of VEGFR-1 is more complex; it both promotes angiogenesis by binding to VEGF-A and potentially regulates this process by antagonizing the VEGF-A/VEGFR-2 interaction.
 
Upon VEGF binding to its receptors, the receptor undergoes a conformational change that activates several downstream signaling pathways, primarily:
1. PI3K/Akt Pathway: This pathway promotes endothelial cell proliferation and survival through Akt phosphorylation.
2. MAPK Pathway: The MAPK pathway induces endothelial cell proliferation and migration.
3. PLC-γ Pathway: Activation of PLC-γ increases intracellular calcium ion concentration, which affects cell morphology and migration.

These signaling pathways collectively regulate the growth, differentiation, and permeability of blood vessels, promoting angiogenesis.
 
VEGF in Angiogenesis
Angiogenesis is the process by which new blood vessels grow from existing vessels. This process is crucial for both normal physiological functions and pathological conditions. In physiological conditions, angiogenesis is involved in processes such as embryonic development, wound healing, and the menstrual cycle. In pathological conditions, angiogenesis is closely associated with tumor growth, retinal diseases, and cardiovascular diseases.
 
Physiological Angiogenesis
Under normal physiological conditions, angiogenesis is regulated by various growth factors, with VEGF-A being the most critical. VEGF-A promotes endothelial cell proliferation, migration, and the formation of vessel lumens by binding to VEGFR-2. VEGF-A plays an essential role not only during embryonic development but also in tissue repair after injury, ensuring an adequate supply of oxygen and nutrients.
 
For instance, during wound healing, VEGF promotes angiogenesis, enhancing local blood circulation and accelerating the healing process. Similarly, VEGF is involved in regulating blood vessel formation in the uterine lining during the menstrual cycle, ensuring a proper blood supply for embryo implantation.
 
Pathological Angiogenesis
In pathological angiogenesis, VEGF plays an even more significant role. Many diseases, including cancer, diabetic retinopathy, and age-related macular degeneration, involve abnormal angiogenesis. Tumor cells secrete VEGF to promote angiogenesis, providing the tumor with the necessary oxygen and nutrients for rapid growth and metastasis.
 
For example, in non-small cell lung cancer (NSCLC) and other tumors, tumor cells overexpress VEGF, stimulating endothelial cell proliferation and migration in the tumor microenvironment. This process not only enhances tumor growth but also facilitates the spread of cancer cells. Targeted therapies that inhibit VEGF or its receptors can effectively suppress angiogenesis and slow tumor growth and metastasis.
 
VEGF in Cancer
Angiogenesis is a key process in tumor growth and metastasis, and VEGF is crucial in promoting angiogenesis within tumors. Tumor cells upregulate VEGF expression to induce endothelial cell proliferation and migration, thereby forming a new vascular network. These new blood vessels supply tumors with oxygen and nutrients and provide pathways for tumor cells to invade and metastasize.
 
Role of VEGF in the Tumor Microenvironment
The tumor microenvironment (TME) consists of tumor cells, surrounding support cells, blood vessels, and immune cells. VEGF’s role in the TME extends beyond promoting angiogenesis; it also regulates immune responses and tumor cell growth. Tumor cells secrete VEGF to induce angiogenesis, enhancing tumor cell proliferation, while simultaneously suppressing immune cell activity to avoid immune system detection.
 
For instance, VEGF binds to VEGFR-2, inhibiting dendritic cell function and reducing anti-tumor immune responses. Additionally, VEGF increases blood vessel permeability, promoting tumor cell invasion and metastasis.
 
Clinical Applications of VEGF Inhibitors
Given VEGF’s critical role in tumor growth, metastasis, and immune evasion, VEGF inhibitors have become widely used in clinical treatment. Anti-VEGF drugs work by preventing VEGF from binding to its receptors, thus reducing angiogenesis and effectively inhibiting tumor growth and metastasis.
 
Clinical Use of Anti-VEGF Drugs
Currently, approved anti-VEGF drugs include Bevacizumab, a monoclonal antibody that binds to VEGF, blocking its interaction with VEGFRs and inhibiting angiogenesis. Bevacizumab has been used to treat various cancers, including non-small cell lung cancer, colorectal cancer, and renal cell carcinoma. Clinical studies have shown that Bevacizumab significantly extends patient survival and improves treatment outcomes.
 
Additionally, VEGF receptor inhibitors such as Sunitinib and Axitinib are also used in clinical practice, especially in the treatment of kidney cancer, gastric cancer, and other malignancies.
 
VEGF in Ophthalmology
In addition to its widespread use in cancer treatment, VEGF plays a critical role in ophthalmic diseases. Many ocular conditions, such as diabetic retinopathy and age-related macular degeneration, are closely associated with excessive angiogenesis. Abnormal VEGF activation in these diseases leads to the formation of new blood vessels, causing retinal hemorrhages, edema, and vision loss.
 
Anti-VEGF drugs such as Ranibizumab and Aflibercept have been widely used in the treatment of ocular diseases. These drugs work by inhibiting VEGF, reducing the formation of abnormal blood vessels, improving retinal blood flow, and slowing the progression of vision loss.
 
Conclusion
VEGF, as a key angiogenic factor, plays an essential role in various physiological and pathological processes. It is crucial in cancer, ophthalmic diseases, cardiovascular diseases, and more. With a deeper understanding of VEGF’s mechanisms, VEGF inhibitors have become an important part of targeted therapy and have shown significant clinical benefits. As new anti-VEGF drugs continue to be developed and applied, VEGF inhibitors are expected to play a key role in the treatment of more diseases, providing patients with more therapeutic options.
 
Click on the product catalog numbers below to access detailed information on our official website.
 
Product Information

S0A4075	Mouse VEGF-A Protein, His Tag	Host : Mouse Expression System : HEK293 Conjugation : Unconjugated
UA040082	VEGF-121 Protein, Human	Host : Human Expression System : E.coli Conjugation : Unconjugated
S0B2372	VEGF Receptor 2/FLK-1 Recombinant Rabbit mAb (SDT-1519-144)	Host : Rabbit Conjugation : Unconjugated
S0B2372P	VEGF Receptor 2/FLK-1 Recombinant Rabbit mAb ，PBS Only(SDT-1519-144)	Host : Rabbit Conjugation : Unconjugated
S0B3083	VEGF-C Recombinant Rabbit mAb (SDT-084-9)	Host : Rabbit
S0B3082	VEGF-C Recombinant Rabbit mAb (SDT-084-2)	Host : Rabbit
S0B3084	VEGF-C Recombinant Rabbit mAb (SDT-084-30)	Host : Rabbit
S0B3085	VEGF-C Recombinant Rabbit mAb (SDT-084-66)	Host : Rabbit
S0B0693	Invivo anti-mouse VEGFR-2 Recombinant mAb	Host : Rat Conjugation : Unconjugated
UA010877	VEGF R2/Flk-1/KDR His Tag Protein, Rhesus macaque	Host : Rhesus macaque Expression System : HEK293 Conjugation : Unconjugated